Sign in
CompletedPhase 3

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Key facts

Who runs it
Vaxcyte, Inc.
Where
Austin, Beaumont, Charlottesville, Cincinnati, DeLand, DeSoto, Detroit, Fort Collins, Hendersonville, Hollywood, Jupiter, Knoxville, Lakeland, Largo, Lenexa, Lexington, Newport News, North Charleston, Omaha, Phoenix, Richmond, Rochester, Salt Lake City, Sunrise, and Valparaiso, United StatesSee the 25 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
1,390 people enrolled
Started
12 Jan 2026
Ended
21 Oct 2026
Type of study
Interventional, 2 groups
Treatments tested
  • 31-valent pneumococcal conjugate vaccine
  • Seasonal Influenza Vaccine (SIV) (Flublok)
  • Placebo
Record updated
13 November 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Male or female ≥50 years of age (inclusive) at the time of randomization into the study
  • Able and willing to complete the informed consent process
  • Available for clinical follow-up through the last study visit at 7 months after the first study vaccination
  • In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator
  • Willing to have blood samples collected and used for research purposes
  • Able to provide proof of identity to the satisfaction of the study site personnel completing the enrollment process
  • Female subjects of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test at Screening and immediately prior to each vaccination and agree to use acceptable contraception, if heterosexually active. Female subjects who are not abstinent from heterosexual intercourse must agree to consistently practice contraception at least 7 days prior to vaccination and through their last study visit. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method ([use condoms with or without spermicide] or have undergone a vasectomy) from Day 1 through their last study visit. Note: A history of amenorrhea for at least 12 months without an alternative medical cause is required for a female to be considered postmenopausal in the study
  • Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary)

Who cannot take part

  • Previous receipt of a licensed or investigational pneumococcal vaccine at any age
  • Previous receipt of an influenza vaccine from the current season; receipt of any influenza vaccine (licensed or investigational) within 6 months prior to Day 1; or receipt/planned receipt of any licensed or investigational non-study influenza vaccine during study participation
  • Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
  • Planned or actual administration of any licensed vaccine within 30 days prior to Day 1
  • Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (participant may be rescreened)
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
  • Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to Day 1
  • Receiving immunosuppressive therapy
  • Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccinations. Note: Receipt of a ≥14-day course of systemic corticosteroids equivalent to ≤10 mg/day is permitted, as are inhaled, nebulized, topical, intra-articular, and intrabursal corticosteroids
  • Current diagnosis of human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
  • History of Guillain-Barré syndrome
  • Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency
  • Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a participant's ability to give informed consent
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
  • History of IPD or pneumococcal pneumonia (either confirmed or self-reported) at any age
  • History of malignancy ≤5 years before to Day 1, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation
  • Employee of, or first-degree relative of any person employed by the Sponsor, the contract research organization (CRO), the Investigator, study site personnel, or site

Where in United States

  • Tekton Research at AustinAustin, United States
  • REX Clinical TrialsBeaumont, United States
  • Charlottesville Medical Research CenterCharlottesville, United States
  • CTI Clinical Research CenterCincinnati, United States
  • University Clinical Research-DelandDeLand, United States
  • Epic Medical ResearchDeSoto, United States
  • DM Clinical Research - DetroitDetroit, United States
  • Tekton Research at Fort CollinsFort Collins, United States
  • DelRicht Research - HendersonvilleHendersonville, United States
  • CenExel Research Centers of AmericaHollywood, United States
  • Health AwarenessJupiter, United States
  • AMR KnxovilleKnoxville, United States
  • Accel Research Sites LakelandLakeland, United States
  • Accel Research Sites - LargoLargo, United States
  • Johnson County ClintrialsLenexa, United States
  • AMR LexingtonLexington, United States
  • Health Research of Hampton Roads, Inc.Newport News, United States
  • Coastal Carolina Research CenterNorth Charleston, United States
  • Velocity OmahaOmaha, United States
  • Hope Research InstitutePhoenix, United States
  • Clinical Research Partners, LLCRichmond, United States
  • Rochester Clinical ResearchRochester, United States
  • CenExel JBR Clinical ResearchSalt Lake City, United States
  • Precision Clinical ResearchSunrise, United States
  • Velocity ValparaisoValparaiso, United States

About the trial

What the trial wants to find out

This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.

The 2 groups in the trial

  • VAX-31 + SIVTreatment being tested

    Participants will receive a single dose of VAX-31 administered as an intramuscular injection at Day 1, concomitantly administered with SIV, followed by placebo at Month 1.

    Treatment: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), and Placebo

  • Placebo + SIVTreatment being tested

    Participants will receive placebo administered via intramuscular injection at Day 1, concomitantly administered with SIV, followed by VAX-31 at Month 1.

    Treatment: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older
Record updated
13 November 2026